Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer

Enrolling by invitation

Conditions studied: Critical Illness, Cancer, Mortality

In brief

This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU). Patients with cancer are highly vulnerable to complications and organ failure, making early risk assessment vital for improving treatment strategies. Researchers will retrospectively review the medical charts and electronic health records of adult patients who stayed in the anesthesia ICU for longer than 24 hours between 2020 and 2025. No new laboratory tests, interventions, or patient contact will occur. The collected data will be analyzed to determine the relationship between initial MPV levels and patient survival outcomes.

Key facts

Study ID

NCT07656311

Run by

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

People needed

425

Starts

2026-06-15

Expected to finish

2026-08-01

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients aged 18 years and older.
• Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
• Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
• Patients with an ICU length of stay longer than 24 hours.
• Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.

You may not qualify if…

• Patients under the age of 18.
• Patients who stayed in the intensive care unit for less than 24 hours.
• Patients with missing or incomplete medical charts, laboratory data, or survival status records.
• Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
• Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.

Where it is running

• Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital — Ankara, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.